IFACTOR BIOLOGIC TRIAL
IFACTOR BIOLOGIC PROFESSIONAL

Case reports may contain a demographic profile of the patient, but usually describe an unusual or novel occurrence. As reported in Wikipedia article, Case Report, in medicine, is a detailed report of the symptoms, signs, diagnosis, treatment, and follow-up of an individual patient. In terms of research annually, USA, India, Japan, Brazil and Canada are some of the leading countries where maximum studies related to Case Report are being carried out. Neurosurg 2018 83(3): 377-84.As per available reports about 75 journals, 550 Conferences, 700 workshops are presently dedicated exclusively to Case Report and about 6,20000 articles are being published on the current trends in Case Report. More information can be found here.ĬFO, Cerapedics Arnold P, Sasso R. This novel mechanism of action is designed to support safer and more predictable bone formation compared to commercially available bone growth factors.

i-FACTOR Peptide Enhanced Bone Graft is the only biologic bone graft in orthopedics that incorporates a small peptide as an attachment factor to stimulate the natural bone healing process. i-FACTOR Peptide Enhanced Bone Graft must be used inside an allograft bone ring and with supplemental anterior plate fixation.Ĭerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform. In the United States, i-FACTOR Peptide Enhanced Bone Graft is indicated for use in skeletally mature patients for reconstruction of a degenerated cervical disc at one level from C3-C4 to C6-C7 following single-level discectomy for intractable radiculopathy (arm pain and/or a neurological deficit), with or without neck pain, or myelopathy due to a single-level abnormality localized to the disc space, and corresponding to at least one of the following conditions confirmed by radiographic imaging (C.T., M.R.I., X-rays): herniated nucleus pulposus, spondylosis (defined by the presence of osteophytes), or visible loss of disc height as compared to adjacent levels, after the failure of at least 6 weeks of conservative treatment.

IFACTOR BIOLOGIC TRIAL

In 2018, the company enrolled the first patients in an IDE clinical trial evaluating the safety and efficacy of its next-generation product, P-15L Peptide Enhanced Bone Graft, for use in patients undergoing TLIF surgery. It is in a new category of bone graft technology and is one of only two drug-device combination products approved by the U.S. The drug-device combination product is based on small peptide (P-15) technology that accelerates new bone formation in patients with degenerative disc disease. for use in anterior cervical discectomy and fusion (ACDF) procedures in 2015. I-FACTOR bone graft has over 10 years of clinical success in Europe and was approved in the U.S. Marx, Ph.D., President, and Chief Operating Officer. The technologies we displace with i-FACTOR don't have cost-effectiveness data, and most have no meaningful clinical data as well,' said Jeffrey G. As our healthcare system becomes ever more focused on value in addition to quality clinical outcomes, this data puts us in a unique position relative to our competition. Ament and his team for conducting this important and infrequently conducted analysis. This comprehensive, cost-effectiveness analysis was the next critical and necessary step to provide clear support for a better alternative to autograft. I-FACTOR has already demonstrated safety and improved outcomes compared to local autograft based on one and two year published data in Spine & Neurosurgery Journals 1,2. In the base-case analysis, both health and societal system costs were evaluated. Two primary outcome measures were assessed: cost and utility.

The study analyzed various real-world scenarios, including inpatient and outpatient surgical settings and private versus public insurances. The patient cohort was extracted from a prospective, multicenter randomized control trial (R.C.T.) from twenty-two North American centers.

IFACTOR BIOLOGIC PROFESSIONAL

Jared Ament, M.D., M.P.H., Director of Outcomes Research and Co-Director of Spine Neurosurgery at the Neurosurgery & Spine Group (N.S.G.) and President and Founder of Neuronomics, a professional corporation specializing in cost-effective analyses in the neurosciences, led this study.

Cerapedics is an ortho-biologics company focused on developing and commercializing its proprietary small peptide (P-15) technology platform.

Ifactor biologic